CHICAGO, June 5, 2017 /PRNewswire/ -- CARsgen Therapeutics (CARsgen), a global biotech start-up focused on developing chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors, disclosed the preliminary safety and efficacy results from a global first-in-man clinical trial of CAR-GPC3 T cell therapy in the treatment for adult patients with relapsed or refractory hepatocellular carcinoma at the 2017 Annual Meeting of American Society of Clinical Oncology (ASCO).